News Hub | News Direct

All Industries


Article thumbnail News Release

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics

NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative diseases and diabetes, in collaboration with iTolerance Inc. (“iTolerance”), a U.S. based regenerative medicine company, announced today the result from the Type B pre-IND meeting held by Kadimastem and iTolerance with a committee of the U.S Food and Drug Administration (“FDA”) on February 24, 2025, regarding the development of iTOL-102, a potential cure for diabetes that would not require life-long chronic immune system suppression. iTOL-102 is an investigational biologic for the treatment and potential cure of Type 1 Diabetes consisting of Kadimastem’s allogenic human stem cell-derived pancreatic islets (IsletRx cells) combined with iTolerance’s immunomodulator (iTOL-100). Kadimastem and iTolerance believe that the completion of the pre-IND meeting is a significant milestone toward the clinical development of iTOL-102, an on-going collaborative research initiative between iTolerance and Kadimastem, funded in part by grants received from the Israel-U.S. Binational Industrial Research and Development Foundation. iTOL-102 was evaluated at the fast-track center for testing at the Diabetes Research Institute (“DRI”) at the University of Miami School of Medicine, where it was designated as a potential breakthrough transplantation approach for the treatment of Type 1 Diabetes, as the novel combination of tolerance-inducing agent and human stem cell-derived islets. iTOL-102 demonstrated functional insulin release and disease reversal in an animal model, with full compatibility between IsletRx cells and iTOL-100. Prior to the meeting with the FDA, Kadimastem and iTolerance received a preliminary response document from the FDA, providing critical feedback on their current preclinical and clinical development plans. This guidance is instrumental in moving forward with the next stages of development. Based on the feedback provided at the pre-IND meeting, Kadimastem and iTolerance are now updating their plans for a safety toxicology study and the preparation of a First-in-Human clinical trial. Kadimastem believes its collaboration with iTolerance signifies a potentially transformative step in diabetes treatment, paving the way towards the potential development of iTOL-100 and requesting regulatory approvals for commercialization of a potential cure for type 1 diabetes. iTOL-100 is an immunomodulatory microgel technology being developed by iTolerance designed to reduce or eliminate the need for life-long chronic systemic immunosuppression following transplantation of allogenic cells. In a preclinical diabetic rodent model designed by iTolerance, iTOL-100 was shown by iTolerance to be compatible with Kadimastem’s IsletRx human stem cell-derived islets. Kadimastem’s IsletRx is a clinical-grade product candidate comprising human pancreatic islet-like cells capable of secreting insulin. IsletRx, a preparation of human stem cell-derived islets developed by Kadimastem, is a scalable and virtually unlimited source of insulin-producing cells which could address the critical shortage of donor islets for transplantation. This innovative therapy may effectively detect glucose levels in the body and produce the necessary amounts of insulin and glucagon. Dr. Anthony Japour, Chief Executive Officer of iTolerance, commented, “I believe that the feedback from the FDA is a critical milestone in the development of iTOL-102, and we are encouraged by their support for our innovative approach to treating Type 1 diabetes. We believe that the successful outcome of this meeting validates our commitment to bring a game-changing therapy to patients, one that could ultimately eliminate the need for chronic life-long immunosuppression. We look forward to continuing our collaboration with Kadimastem and working closely with the FDA.” Alex Zwyer, CEO of NLS, commented, “I believe that the news demonstrates the strength of the proposed merger of NLS and Kadimastem and its technology platform to build a healthy, strong merged company that will benefit shareholders.” Kadimastem Executive Chairman and CEO Ronen Twito said, "The promising results from the fast-track center for testing at the DRI, combined with the comprehensive studies conducted by iTolerance and Kadimastem, enabled us to complete this important milestone. We are working closely with the FDA on the necessary steps needed to implement this potential innovative technology for patients with Type 1 diabetes and demonstrate a novel islet cell transplantation approach with no need for immunosuppression.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About iTolerance, Inc. iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islet to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. We are a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements when they discuss the belief that the results of the pre-IND meeting with the FDA demonstrates the strength of the proposed merger; that the meeting with the FDA is a significant milestone in the development of iTOL-102, and the expected benefits of iTOL-102 in the treatment of diabetes. These forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the companies’ ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully completing their clinical trials; the companies’ products may not be approved by regulatory agencies; their technologies may not be validated as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties may develop with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; the companies’ patents may not be sufficient; their products may harm recipients; changes in legislation may adversely impact either or both of the companies; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate products to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading “Risk Factors” in NLS’s annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent filings made by NLS with the SEC, including under the heading “Risk Factors” in NLS’s registration statement on Form F-4, filed with the SEC on December 27, 2024. This press release may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the company's activity, as well as developments in the general environment and external factors affecting the company's activity. The company's results and achievements in the future may differ materially from any presented herein and the company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This press release does not constitute a proposal to purchase the company's securities or an invitation to receive such offers. Investment in securities in general and in the company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. No Offer or Solicitation: This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Additional Information about the Transaction and Where to Find ItIn connection with the proposed transaction, NLS has filed a Registration Statement on Form F-4, including a proxy statement/prospectus, with the SEC. NLS may also file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important information about NLS and Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS’s website at www.nlspharma.com. Participants in the Solicitation: NLS, Kadimastem, and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in NLS’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the SEC on May 15, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above. Contact Details NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd. +41 44 512 21 50 contact@nls-pharma.com Kadimastem Ltd. Sarah Bazak +972 73-797-1615 s.bazak@kadimastem.com Company Website https://nlspharmaceutics.com/

February 25, 2025 07:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Robertson Stephens Launches Family Office for Select Clients

Robertson Stephens

Robertson Stephens today announced that it has hired Bruce Stewart to launch a family office that will serve select ultra-high-net-worth clients who have outgrown a multi-family office platform but are not ready to transition to a pure single-family office environment. As Head of Family Office at Robertson Stephens, Stewart brings over 25 years of experience in building and advising single-family offices, as well as serving as an outsourced chief investment officer. In this role, he will develop a practice designed for families with more sophisticated needs than those typically addressed by traditional multi-family offices. “We have always planned to have a family office service offering adjacent to our wealth management practice,” said Raj Bhattacharyya, Chief Executive Officer of Robertson Stephens. “With the launch of our family office, clients have the rare opportunity to access unique and highly valuable services beyond the standard offering seen in traditional private banks, multi-family offices and many other players in the industry without the upfront and high recurring expenses typical of a single-family office. Bruce is not only a deep expert in this space, he has also demonstrated his ability to build out successful single-family offices over the past few years.” Before Robertson Stephens, Stewart was the founder and Managing Partner of Spartan Risk Solutions (SRS), a discreet family-office consultancy specializing in the development of family offices and outsourced chief investment officer solutions. In this role, Stewart built and managed $23 billion in wealth for four families. Previously, Stewart was the global head of investments for Bank of New York Family Office, where he led an investment team managing nearly $15 billion in assets. His other leadership roles include having served as President of BNY Mellon Canada and co-head of investments at Toronto Dominion Bank. “I’m grateful to Robertson Stephens for this opportunity to build out this first-of-its-kind service,” Stewart said. "In my experience, some families have outgrown the capabilities of a traditional multi-family office but prefer to avoid the financial commitment of establishing their own. These families have more complex needs that require a specialized skill set, enhanced capabilities, and a sophisticated approach. I’m excited to build this practice at Robertson Stephens and deliver a truly differentiated solution." Contact Details Peter Page ppage@vocatusllc.com Company Website https://rscapital.com/

February 24, 2025 12:33 PM Eastern Standard Time

Article thumbnail News Release

Robertson Stephens Launches Family Office for Select Clients

Robertson Stephens

Robertson Stephens today announced that it has hired Bruce Stewart to launch a family office that will serve select ultra-high-net-worth clients who have outgrown a multi-family office platform but are not ready to transition to a pure single-family office environment. As Head of Family Office at Robertson Stephens, Stewart brings over 25 years of experience in building and advising single-family offices, as well as serving as an outsourced chief investment officer. In this role, he will develop a practice designed for families with more sophisticated needs than those typically addressed by traditional multi-family offices. “We have always planned to have a family office service offering adjacent to our wealth management practice,” said Raj Bhattacharyya, Chief Executive Officer of Robertson Stephens. “With the launch of our family office, clients have the rare opportunity to access unique and highly valuable services beyond the standard offering seen in traditional private banks, multi-family offices and many other players in the industry without the upfront and high recurring expenses typical of a single-family office. Bruce is not only a deep expert in this space, he has also demonstrated his ability to build out successful single-family offices over the past few years.” Before Robertson Stephens, Stewart was the founder and Managing Partner of Spartan Risk Solutions (SRS), a discreet family-office consultancy specializing in the development of family offices and outsourced chief investment officer solutions. In this role, Stewart built and managed $23 billion in wealth for four families. Previously, Stewart was the global head of investments for Bank of New York Family Office, where he led an investment team managing nearly $15 billion in assets. His other leadership roles include having served as President of BNY Mellon Canada and co-head of investments at Toronto Dominion Bank. “I’m grateful to Robertson Stephens for this opportunity to build out this first-of-its-kind service,” Stewart said. "In my experience, some families have outgrown the capabilities of a traditional multi-family office but prefer to avoid the financial commitment of establishing their own. These families have more complex needs that require a specialized skill set, enhanced capabilities, and a sophisticated approach. I’m excited to build this practice at Robertson Stephens and deliver a truly differentiated solution." About Robertson Stephens Robertson Stephens Wealth Management, LLC is an independent SEC-registered investment advisor. Registration does not imply any specific level of skill or training and does not constitute an endorsement of the firm by the Commission. Its mission is to transform the wealth management experience by delivering institutional-quality investment solutions, comprehensive wealth planning, and intelligent digital solutions all within a fiduciary relationship where the client is our highest priority. Robertson Stephens AUM is as of December 2024. For more information about Robertson Stephens, please visit: https://www.rscapital.com. Contact Details Peter Page ppage@vocatusllc.com Company Website https://rscapital.com/

February 24, 2025 12:05 PM Eastern Standard Time

Article thumbnail News Release

Where is WOW Vegas Legal in the US?

Acroud Media

WOW, Vegas Casino has been one of the online social casinos for a while, offering fantastic no-deposit offers, casino-style games, and more. It has certainly made its mark, attracting players from across the US thanks to its incredible customer features. The brand's priority is to please players. Where is WOW Vegas Legal? Players aged 18+ can visit WOW Vegas Casino from all US states. However, at this current time, the states of Washington, Idaho, Nevada, and Michigan, are excluded and do not accept online Social, or Sweepstakes Casinos. Despite the restricted states, WOW Vegas is largely accessible in comparison to a traditional casino site. As well as the broad legality of WOW Vegas, another key aspect to remember is that to register and participate in activities at WOW Vegas Casino, individuals must be 18 years or older and reside in a state not subject to the four aforementioned restrictions. Our Expert Review of WOW Vegas WOW Vegas Casino stands as a mecca for exemplary casino-style experiences and entertainment within the online casino industry. Recognized for its enthralling features and immersive gameplay, WOW Vegas delivers an exhilarating experience to players across the US, featuring a diverse selection of state-of-the-art games, spanning from traditional table games to inventive slots and live dealer options. Its intuitive interface and seamless navigation elevate the overall experience, ensuring players can explore and enjoy its extensive offerings effortlessly. Backed by rigorous security measures, players can engage in their favorite games with assurance, confident that their information remains protected. Furthermore, WOW Vegas offers many enticing promotions catering to loyal players and newcomers alike. Being a social site, WOW Vegas does not offer real money play; instead, virtual currencies known as WOW and Sweeps Coins are utilized to access free casino-style games and redeem prizes. Partaking in WOW Vegas is entirely free, so users do not have to risk their hard-earned cash. Create an account with WOW Vegas Casino today! Restricted States for WOW Vegas Idaho Michigan Nevada Washington 18+ Please Play Responsibly. Gambling Problem? Call or text 1-800-GAMBLER Why is WOW Vegas Restricted? Despite being widely legal across the US, WOW Vegas Casino is still restricted in states including Idaho, Michigan, Nevada, and Washington because of differing legal regulations concerning online gambling that vary from state to state. Each state maintains its unique laws and policies governing gambling activities, and some states enforce strict regulations or complete prohibitions on online gambling, while others adopt more lenient laws. Concerns regarding addiction, consumer protection, and adherence to state gambling policies influence these restrictions. For example, regardless of whether it is a social site or a traditional casino, Washington does not allow any form of gambling. Thus, the varying legal landscape across states dictates the accessibility and operation of online casinos like WOW Vegas Casino. Legalities of Social Casinos US Our valued readers may need to be made aware of the laws surrounding social casino sites like WOW Vegas. Therefore, our experts are here to provide a simple explanation of the legalities surrounding WOW Vegas and social sites alike. One of the main differences between traditional sites and social casinos is the lack of real money play. WOW Vegas utilizes WOW Coins and Sweeps Coins in place of cash. WOW, Coins can be used to access free casino-style games and can be purchased via coin packages or won through bonuses. Sweep Coins cannot be purchased; they can only be won unless players receive additional Sweep Coins within their WOW Coin packages. Sweep coins are used for accessing games as well as redeeming prizes like real cash. Therefore, partaking in social casinos is entirely free unless users wish to purchase coin packages. Additionally, the minimum gambling age for social sites like WOW Vegas is lower than traditional casinos, at 18+. To be eligible to create an account with a social casino site, users must ensure they are residing in a non-restricted state and are aged 18+. FAQs Is WOW Vegas Casino Safe? Players can rest assured that WOW Vegas Casino is highly safe and has received valid licensing and certification from reliable licensing bodies. Additionally, WOW Vegas adopts SSL data encryption technology to protect all user data and information. Where Can I access WOW Vegas? WOW Vegas is legal in all US states, excluding Nevada, Michigan, Idaho, and Washington. Is there a WOW Vegas App? There is currently no WOW Vegas Casino mobile app; however, players can enjoy the fully optimized WOW Vegas mobile site for iOS and Android devices. Users can find their favorite casino games and generous customer bonuses here. [toc] Contact Details Acroud Media info-media@acroudmedia.com

February 24, 2025 09:10 AM Eastern Standard Time

Article thumbnail News Release

TriSpan Closes Continuation Vehicle for Prestige PEO Holdings

PrestigePEO

TriSpan LLP (“TriSpan”), a New York and London based private equity firm, is pleased to announce the closing of a single-asset continuation vehicle that acquired interests in Prestige PEO Holdings LP (“Prestige” or the “Company”). The transaction was led by growth equity firm Lead Edge Capital, and supported by a diverse group of existing investors, including a substantial investment from affiliates of TriSpan. The transaction will provide follow-on capital to support Prestige through its next phase of growth and value creation. Prestige is the parent company of PrestigePEO, a provider of comprehensive, outsourced human resource services to small and mid-size businesses in the United States. Since TriSpan’s original investment in 2020, Prestige has grown organically utilizing its differentiated broker model while also successfully completing five strategic acquisitions and expanding into attractive geographies. “We are thrilled to continue our collaboration with TriSpan as we continue to capitalize on a tremendous market opportunity in our next phase of growth,” said Andy Lubash, CEO and Founder of Prestige. “Our partnership with TriSpan has been core to our success and we believe we are well-positioned to continue to gain market share and unlock the full growth potential of the platform.” “Prestige’s talented leadership team and its ability to access the broker channel for new client acquisitions has driven strong performance to-date and will continue to be an accelerator of growth in the future,” said Baudoin Lorans, Partner at TriSpan. “The Company’s high-touch, customer centric approach delivers substantial value to its clients and leads to impressive retention. We are delighted to continue our partnership with the Company and its leadership team.” “We are excited to partner with Prestige and TriSpan on this next phase of expansion,” said Tim Bemer, Partner at Lead Edge. “For over two decades, Prestige has demonstrated an impressive track record of efficient growth and high client satisfaction, driven by a strong leadership team and unique go-to-market strategy.” Lazard Frères & Co. LLC served as financial advisor and Goodwin Procter LLP served as legal counsel to TriSpan. A separate team of attorneys at Goodwin Procter LLP served as legal counsel to Lead Edge on the transaction. Atlantic Global Risk LLC served as the R&W insurance broker for the transaction and a fairness opinion was provided by Houlihan Lokey Capital Inc. About Prestige Prestige PEO Holdings, LLC is the parent company of Prestige Employee Administrators, also known as PrestigePEO. Prestige empowers small and mid-sized businesses to simplify HR by offering end-to-end support for employee benefits management, payroll administration, workers’ compliance, HR guidance, and more. Merging the power of industry-leading customer service with innovative technology options, Prestige delivers a full spectrum of HR services and solutions to help SMBs lower employee benefit costs, reduce administrative workloads, and manage critical HR functions. Prestige is among only 1% of PEOs that are ESAC-accredited, Workers Comp Risk Management (CI)-certified, and classified as a Certified Professional Employer Organization (CPEO) by the IRS – demonstrating financial stability and strict adherence with a diverse range of regulatory and security standards. Headquartered in Melville, NY, Prestige is licensed to support SMBs nationwide. For more on Prestige, visit www.prestigepeo.com. Follow the Company on Facebook, X, LinkedIn, Instagram, and YouTube. About TriSpan Founded in 2015, TriSpan, LLP is a private equity firm with offices in New York and London that invests in middle market companies in North America, Europe, and the United Kingdom. TriSpan, LLP is committed to creating value through using a combination of deep operational and financial resources to accelerate growth and drive improved performance. Since inception, the firm has completed 24 platform investments, alongside nearly 100 bolt-on acquisitions across its portfolio. For more information, please visit Trispanllp.com. About Lead Edge Capital Lead Edge Capital is a $5 billion growth equity firm investing in software, internet, and tech-enabled businesses globally. The firm has invested in a number of major software and internet companies around the world, including Alibaba Group, Arrive Logistics, Asana, Azul Systems, Bazaarvoice, Benchling, Clearscore, Duo Security, Grafana, GrowthZone, Holistiplan, LeanStaffing, LiveView Technologies, Pacemate, SafeSend, Signal Sciences, Tempo, Toast, Wise, and YouSign. One of the main drivers of Lead Edge’s success is its unique investor base, a network of 700+ executives, entrepreneurs, and dealmakers who have built and run some of the world’s most successful companies. In addition to providing flexible capital, Lead Edge leverages this global advisory group to connect portfolio companies with the customers, partners, talent, and advisors needed to accelerate growth. Lead Edge Capital was founded in 2011 and has offices in New York City, London and Santa Barbara. Contact Details Prestige PEO Holdings, LLC Jay Zamft +1 516-692-8505 jzamft@prestigepeo.com Company Website https://www.prestigepeo.com/

February 24, 2025 09:00 AM Eastern Standard Time

Article thumbnail News Release

Elluminex (ELX): New Decentralized Exchange Spearheading DeFi Revolution On Toncoin Nertwork

Elluminex

The decentralized finance space has changed over the years and appears ready to replace traditional finance institutions, which have faced significant regulatory scrutiny, security, and privacy issues. According to Forbes, the DeFi market could explode to over $450B by 2030, which is more than 300% growth from its current market size. Elluminex (ELX) is ideally positioned to grab a share of this growing market thanks to its revolutionary DeFi hub on the TON blockchain. This new project could transform the largely untapped Toncoin network, much like how Jupiter (JUP) revolutionized Solana to become one of the dominant players in DeFi. Since Jupiter's launch, Solana has become a goldmine of explosive meme coin opportunities. Now, market participants anticipate that TON could benefit from its Jupiter-like platform―Elluminex (ELX). Let’s find the possibilities! Elluminex (ELX) To Drive DeFi Adoption On Toncoin Network Despite being among the fastest-growing blockchains, Toncoin is underdeveloped, mainly in terms of the DeFi landscape. However, this might soon change, thanks to Elluminex (ELX). The DeFi platform seeks to leverage the over 950 million users in the network to bring DeFi to the blockchain, transforming it and taking its capabilities and vast reach to the next level. The altcoin seeks to combine fragmented liquidity and leverage TON’s scalability and speed to power cross-chain swaps across 40 networks. Therefore, traders on TON will access liquidity from major networks. This increased liquidity will ensure a more efficient trading experience, minimizing slippage, which is critical for traders since slippage usually eats into profits. This will, in turn, stabilize prices in the TON ecosystem. With this view, more developers could launch on the chain. Jupiter brought this to the Solana network when it launched. Additionally, the project’s non-custodial approach, which does not require rigorous KYC processes, enables users to retain complete control over their assets. What Features Are Triggering Elluminex Adoption? Elluminex seeks to provide a seamless and user-friendly platform that allows users to trade, stake, farm, bridge, and track their portfolios. By combining these features in a single unified platform, Elluminex could open up the DeFi space for beginners and experienced users. The decentralized exchange enables users to trade an array of crypto assets from their wallets to ensure security and control. To empower informed decision-making, Elluminex features an AI portfolio tracker that enables traders to monitor, analyze, and gain insights into their assets’ performance. It also has a comprehensive educational academy that helps users broaden their knowledge of Decentralized finance (DeFi). Additionally, the platform has a pre-market access feature, where users gain early access to new TON projects through an over-the-counter platform before they are officially launched on significant exchanges. This opens the door to opportunities for traders to enter high-potential projects at the nascent stage. Outside of that, users can earn rewards by staking the token and offering liquidity to the ecosystem. ELX Token Set For Exponential Rallies The ELX token will power significant processes within its ecosystem, including governance and staking rewards. At the ongoing presale, Elluminex is selling for only $0.06. Given its innovative features and a focus on accessibility, Elluminex could see exponential growth before the end of its presale, positioning it among the best crypto to watch in 2025. The presale just started a few weeks ago, and Elluminex has already raised over $300,000 in ICO funding. This attests to its growing demand and growth potential. Now could be the best time to join the Elluminex revolution, as it stands a chance of making massive returns. With its cross-chain capabilities and TON’s affiliation with Telegram's nearly 1 billion users, ELX's price will likely skyrocket in the months ahead. This makes it the best DeFi coin to buy now. Join the community and make Elluminex part of your portfolio today! Website: elluminex.com/ X (Twitter): https://x.com/elluminex Telegram: https://t.me/Elluminex YouTube: https://www.youtube.com/@Elluminex Elluminex is unique in that it is bringing DeFi to the TON Network/Blockchain which at the moment is very limited in this sense with very few options available to its users. Despite this the TON Network is still the fastest growing blockchain in the world and many view it as a future powerhouse to rival Bitcoin, Ethereum and Solana. By bringing DeFi to the TON Network, it would immediately transform the chain and take its capabilities and vast reach to the next level. (ELX is a transformative crypto for the TON chain) Simply having lots of token holders and liquidity means nothing if project owners, developers are not able to tap into and utilise it, and crypto users are not able to trade it freely and seamlessly. Cryptocurrency may be unregulated in your jurisdiction. The value of cryptocurrencies fluctuates and it is important that you thoroughly understand the risks associated with acquiring cryptocurrencies, as outlined in the Disclaimer. You confirm that you are not a citizen or resident of the United States, United Kingdom, or any prohibited jurisdiction, or any other location where the purchase of Elluminex and $ELX token may be legally restricted. Please note that our list of restricted countries and terms of service may undergo updates, and it is your responsibility to stay informed about the latest version. By proceeding to continue to use Elluminex.com, you acknowledge and agree to our Terms of Use and Privacy Policy. Contact Details Elluminex Andy press@elluminex.com Company Website https://elluminex.com/

February 24, 2025 07:31 AM Eastern Standard Time

Image
Article thumbnail News Release

World Mobile Recognized as ITB Innovator 2025 for Transforming Global Travel Connectivity

Rev Up Marketers

World Mobile has been named an ITB Innovator 2025 by ITB Berlin, the world’s leading travel trade show, in recognition of its groundbreaking advancements in travel technology. This prestigious honor highlights World Mobile’s role in redefining global travel connectivity through its unlimited travel eSIM, which offers seamless, high-speed internet access across more than 120 countries. With international travel on the rise, the demand for reliable, cost-effective connectivity has never been greater. Traditional roaming fees, SIM card swaps, and unreliable public Wi-Fi have long been pain points for travelers. World Mobile has addressed these challenges by establishing partnerships with over 250 mobile networks worldwide, ensuring a seamless and uninterrupted internet experience for users. Haim Boukai, Senior VP of Business Development at World Mobile, described the recognition as a validation of the company’s commitment to revolutionizing travel connectivity. He emphasized that in an increasingly digital world, staying connected should be effortless, affordable, and worry-free. Unlike traditional SIM cards and many existing eSIM solutions, World Mobile’s technology enables travelers to stay online without concern about data limits, hidden fees, or unreliable connections. By automatically connecting to the strongest available local network, it provides uninterrupted global access, setting a new standard for travel connectivity. The ITB Innovator 2025 award not only underscores World Mobile’s leadership in travel technology but also presents a valuable opportunity for airlines, travel agencies, and hospitality providers to integrate seamless eSIM solutions into their services. As the demand for digital solutions grows, travel businesses can enhance customer experience and offer a more connected journey. Looking ahead, World Mobile is actively investing in next-generation connectivity solutions, including AI-driven network optimization, enhanced 5G integration, and strategic partnerships with major travel platforms. With a commitment to continuous innovation, the company remains at the forefront of digital transformation in the travel industry. About World Mobile Founded in 2019, World Mobile is a leading provider of global travel connectivity solutions. By leveraging cutting-edge eSIM technology and strategic partnerships with over 250 mobile networks, the company ensures seamless, high-speed internet access across more than 120 countries. Its unlimited travel eSIM is designed to eliminate the complexities of traditional roaming, offering travelers an affordable and hassle-free way to stay connected. For more detail Visit: https://www.worldmobile.com/ Contact Details World Mobile Haim Boukai affiliate@worldmobile.com Company Website https://www.worldmobile.com/

February 24, 2025 05:55 AM Eastern Standard Time

Article thumbnail News Release

Towerstone Accountants Launches Inheritance Tax Advisory Service Amid Upcoming Pension Tax Changes

Rev Up Marketers

Towerstone Accountants has announced the launch of a specialized Inheritance Tax Advisory Service to help individuals navigate the significant upcoming changes to pension taxation. With new rules set to take effect in 2027, unspent pension funds will become subject to Inheritance Tax (IHT) at 40%, potentially impacting thousands of families. Proactive Planning for Changing Tax Rules For years, pensions have served as a tax-efficient way to pass down wealth. However, under the revised regulations, any remaining pension funds at the time of death will be included in the deceased’s estate, making them subject to IHT. "Many individuals have structured their financial plans around the assumption that pensions are outside the IHT net," said Christina Odgers, Managing Director at Towerstone Accountants. "This change requires a proactive approach, and our new Inheritance Tax Advisory Service is designed to help clients safeguard their wealth." Tailored Strategies for Tax Efficiency Towerstone Accountants’ Inheritance Tax Advisory Service will provide personalized strategies, including: Optimized Pension Withdrawals – Advising clients on the most tax-efficient ways to draw down their pension while reducing their estate’s taxable value. Early Gifting Plans – Helping clients leverage HMRC’s tax-free gifting rules, ensuring funds reach their loved ones instead of being lost to tax. Alternative Investment Planning – Exploring tax-efficient investment options, such as Business Relief-qualifying assets, to protect wealth from IHT. Estate Structuring & Trusts – Assisting clients in setting up trusts and maximizing available allowances for spouses, civil partners, and charities. Helping Clients Stay Ahead of HMRC With the 2027 deadline fast approaching, Towerstone Accountants urges individuals to review their estate plans now. "Waiting until the last minute could mean losing a significant portion of your inheritance to tax," said Laura Stevenson, Estate Planning Expert. "Our team is ready to help clients develop robust tax strategies tailored to their needs." Book a Consultation Today Towerstone Accountants is now offering free initial consultations for individuals concerned about the upcoming IHT changes. To learn more or schedule an appointment, visit https://www.towerstone.co.uk/ or contact the estate planning team directly. About Towerstone Accountants Towerstone Accountants is a leading advisory firm specializing in tax planning, wealth management, and estate strategies. With a team of experts dedicated to minimizing tax liabilities and preserving family wealth, Towerstone provides tailored financial solutions for individuals and businesses alike. Contact Details Towerstone Accountants Ltd Christina Odgers +44 1234 889034 Christina@towerstone.co.uk Company Website https://www.towerstone.co.uk/

February 24, 2025 05:52 AM Eastern Standard Time

Image
Article thumbnail News Release

Avensure Reviews Key Leadership & Announces Promotions To Enhance Innovation And Excellence

Rev Up Marketers

Avensure is excited to announce the promotion of Joy Gateley, who has been promoted to Director of Service Delivery and Julie Davenport who has been promoted to Finance Director. These promotions reflect our ongoing commitment to innovation and excellence in HR, health and safety, and Employment Law outsourced compliance services. We're proud to have Joy and Julie step into these leadership roles to help us continue supporting businesses across the UK as we always do. With Recent Milestones Developments in Mind, Avensure Reviews The Last 6 Months of 2024 Over the past six months of 2024, Avensure saw fantastic growth across various teams. This includes the addition of several talented people to our business, services, marketing, and software development teams, including the creation of our "Genius Team" focused on Avensure PeopleCloud software. We’re thrilled about this progress as it enhances our ability to deliver even better solutions for UK businesses. What Distinguishes Avensure from Industry Competitors? Avensure prides itself on being different. What truly sets Avensure apart is our personalised approach—it's not just a buzzword for us. From the very start, we’ve been committed to delivering bespoke solutions, with designated lead advisors who bring sector-specific expertise. At Avensure, we pride ourselves on offering a level of support that goes beyond the typical call centre approach many businesses adopt—we’ve built this into our core philosophy. Don’t just take our word for it—our client reviews speak for themselves, showing that our commitment to personalised service has been there from day one. Managing Director, Chris Garner, Said: "Joy and Julie have both been very instrumental in Avensure’s growth and success. Their leadership has been key to our strong performance over the years. I'm excited to welcome them both to the Board, where they will continue to drive our mission to provide expert HR and compliance solutions to businesses across the UK," says Chris Garner, Managing Director of Avensure. About Avensure H&S & HR Outsourcing Services Avensure H&S HR Outsourcing Services is a leading provider of HR, employment law and health & safety outsourcing. With over 5,000 clients Avensure helps UK businesses stay up to date with changing legislation and grow and protect in the long term. Contact Details Avensure H&S & HR Outsourcing Services Chris Garner +44 330 100 8705 enquiries@avensure.com Company Website https://www.avensure.com/

February 24, 2025 05:49 AM Eastern Standard Time

Image
1 ... 2122232425 ... 3853